Loading...
Loading...
ICVX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.8M |
| Gross Profit | -0.8M |
| Operating Expense | 25.3M |
| Operating I/L | -25.3M |
| Other Income/Expense | 3.2M |
| Interest Income | 3.2M |
| Pretax | -22.0M |
| Income Tax Expense | -0.8M |
| Net Income/Loss | -22.0M |
Icosavax, Inc. is a biopharmaceutical company specializing in the development of vaccines for life-threatening respiratory diseases using its virus-like particle (VLP) platform technology. The company's pipeline includes IVX-121, a vaccine candidate targeting RSV under Phase 1/1b clinical trial; IVX-A12, a RSV/hMPV bivalent antigen candidate; IVX-241, targeting hMPV; and IVX-411, an original RBD sequence antigen with SARS-CoV-2 target under Phase 1/2 clinical trial.
